Dossier assessment
Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
Added benefit not proven
Project details
- Project no.
- A21-09
- Commission
- Commission awarded on 20.01.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Pertuzumab/trastuzumab (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pertuzumab/trastuzumab (breast cancer, neoadjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed